Kura Oncology, Inc. (KURA) Stock Rating Upgraded by Zacks Investment Research
Kura Oncology, Inc. (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday. The brokerage currently has a $7.75 price objective on the stock. Zacks Investment Research‘s price objective points to a potential downside of 34.32% from the stock’s previous close.
According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “
A number of other research analysts have also recently commented on the stock. Cowen and Company started coverage on shares of Kura Oncology in a research report on Thursday. They issued an “outperform” rating on the stock. Cann reaffirmed a “buy” rating and issued a $16.00 target price on shares of Kura Oncology in a research report on Monday, May 15th. Oppenheimer Holdings, Inc. set a $16.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research report on Wednesday, June 14th. ValuEngine cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Citigroup Inc. set a $13.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research report on Tuesday, August 8th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $14.15.
Kura Oncology (NASDAQ KURA) opened at 11.80 on Friday. The stock’s market cap is $235.86 million. Kura Oncology has a 1-year low of $4.00 and a 1-year high of $13.80. The company has a 50-day moving average of $7.97 and a 200 day moving average of $8.71.
Kura Oncology (NASDAQ:KURA) last posted its earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.03. Analysts predict that Kura Oncology will post ($1.55) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Kura Oncology, Inc. (KURA) Stock Rating Upgraded by Zacks Investment Research” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/09/kura-oncology-inc-kura-stock-rating-upgraded-by-zacks-investment-research.html.
A number of large investors have recently modified their holdings of the business. California State Teachers Retirement System purchased a new stake in Kura Oncology during the second quarter worth about $235,000. State Street Corp purchased a new stake in Kura Oncology during the second quarter worth about $1,394,000. OxFORD Asset Management LLP purchased a new stake in Kura Oncology during the second quarter worth about $217,000. Vanguard Group Inc. increased its stake in Kura Oncology by 13.0% during the second quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock worth $4,035,000 after purchasing an additional 50,033 shares during the period. Finally, Northern Trust Corp increased its stake in Kura Oncology by 939.3% during the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock worth $1,372,000 after purchasing an additional 133,293 shares during the period. Institutional investors own 39.07% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.